ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT01970982
Previous Study | Return to List | Next Study

Reduced Exposure Study in Smokers Using the Tobacco Heating System 2.2 (THS 2.2) for 5 Days in a Confinement Setting

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01970982
Recruitment Status : Completed
First Posted : October 28, 2013
Results First Posted : October 17, 2016
Last Update Posted : October 17, 2016
Sponsor:
Information provided by (Responsible Party):
Philip Morris Products S.A.

Brief Summary:
The overall goal of the study is to evaluate if the ad libitum use of the Tobacco Heating System 2.2 (THS 2.2) for 5 consecutive days by adult Japanese healthy smokers affects the levels of biomarkers of exposure for selected harmful and potentially harmful constituents (HPHCs) compared to smoking conventional cigarettes (CC) and smoking abstinence (SA).

Condition or disease Intervention/treatment Phase
Smoking Other: Tobacco Heating System (THS 2.2) Other: Smoking abstinence (SA) Other: Conventional cigarette (CC) Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 166 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: A Controlled, 3-arm Parallel Group Study to Demonstrate Reduction in Exposure to Smoke Constituents in Healthy Smokers Switching to THS 2.2 or to Smoking Abstinence, Compared to Conventional Cigarettes for 5 Days in Confinement
Study Start Date : July 2013
Actual Primary Completion Date : December 2013
Actual Study Completion Date : July 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Smoking

Arm Intervention/treatment
Experimental: Tobacco Heating System (THS 2.2)
Ad libitum use of THS 2.2 for 5 days in confinement
Other: Tobacco Heating System (THS 2.2)
THS 2.2 ad libitum for 5 days in confinement

Sham Comparator: Smoking abstinence (SA)
Abstinence from smoking for 5 days in confinement
Other: Smoking abstinence (SA)
SA for 5 days in confinement

Active Comparator: Conventional cigarette (CC)
Ad libitum use of Subject's own preferred brand of CC for 5 days in confinement
Other: Conventional cigarette (CC)
Subject's own preferred brand of CC ad libitum for 5 days in confinement




Primary Outcome Measures :
  1. Concentration of Monohydroxybutenyl Mercapturic Acid (MHBMA) [ Time Frame: 5 days ]

    Concentrations measured at Day 5 in urine, adjusted for creatinine.

    Geometric Least Squares LS) means are provided as descriptive statistics.


  2. Concentration of 3-hydroxypropylmercapturic Acid (3-HPMA) [ Time Frame: 5 days ]

    Concentrations measured at Day 5 in urine, adjusted for creatinine.

    Geometric Least Squares means are provided as descriptive statistics.


  3. Concentration of S-phenylmercapturic Acid (S-PMA) [ Time Frame: 5 days ]

    Concentrations measured at Day 5 in urine, adjusted for creatinine.

    Geometric Least Squares means are provided as descriptive statistics.


  4. Levels of Carboxyhemoglobin (COHb) [ Time Frame: 5 days ]

    % COHb blood measurements performed in the evening of Day 5, expressed as % of saturation of hemoglobin.

    Geometric Least Squares means are provided as descriptive statistics.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   23 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subject is Japanese.
  • Smoking, healthy subject as judged by the Investigator.
  • Subject smokes at least 10 commercially available non-menthol CCs per day (no brand restrictions) for the last 4 weeks, based on self reporting.
  • Subject has smoked for at least the last 3 consecutive years.
  • Subject does not plan to quit smoking in the next 3 months.

Exclusion Criteria:

  • As per Investigator judgment, the subject cannot participate in the study for any reason (e.g., medical, psychiatric, and/or social reason).
  • The subject has received medication within 14 days or within 5 half-lives of the medication (whichever is longer), which has an impact on CYP1A2 or CYP2A6 activity.
  • For women: Subject is pregnant or is breast feeding.
  • For women: Subject does not agree to use an acceptable method of effective contraception.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01970982


Locations
Japan
Higashi Shinjuku Clinic, Daito Building, 1-11-3, Okubo, Shinjuku-ku
Tokyo, Japan
Sponsors and Collaborators
Philip Morris Products S.A.
Investigators
Principal Investigator: Takuya Kunito, MD Higashi Shinjuku Clinic
Study Chair: Christelle Haziza, PhD Philip Morris Products S.A.

Responsible Party: Philip Morris Products S.A.
ClinicalTrials.gov Identifier: NCT01970982     History of Changes
Other Study ID Numbers: ZRHR-REXC-04-JP
ZRHR-REXC-04-JP ( Other Identifier: Philip Morris Products S.A. )
First Posted: October 28, 2013    Key Record Dates
Results First Posted: October 17, 2016
Last Update Posted: October 17, 2016
Last Verified: August 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Philip Morris Products S.A.:
Candidate modified risk tobacco product
Conventional cigarette
Reduced exposure
HPHCs
Confinement